Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed

We have shown that low-dose alemtuzumab is effective for GVHD prevention, but its use still impairs the immune reconstitution.